|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 115.87 USD | +2.54% |
|
+2.17% | +10.08% |
| 05-20 | National Advertising Review Board refers Merck animal health to FTC & FDA for Bravecto Quantum dosing claims | RE |
| 05-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
Company Valuation: Merck & Co., Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 193,588 | 281,302 | 276,259 | 251,648 | 261,258 | 279,090 | - | - |
| Change | - | 45.31% | -1.79% | -8.91% | 3.82% | 6.83% | - | - |
| Enterprise Value (EV) 1 | 218,594 | 298,801 | 304,221 | 275,517 | 296,032 | 315,470 | 303,012 | 286,023 |
| Change | - | 36.69% | 1.81% | -9.44% | 7.45% | 6.57% | -3.95% | -5.61% |
| P/E ratio | 14.9x | 19.4x | 779x | 14.8x | 14.5x | 50.4x | 13.6x | 11.8x |
| PBR | 5.07x | 6.12x | 7.34x | 5.44x | 5.01x | 5.74x | 4.76x | 3.91x |
| PEG | - | 1.7x | -8x | 0x | 1.81x | -0.7x | 0x | 0.8x |
| Capitalization / Revenue | 3.97x | 4.75x | 4.6x | 3.92x | 4.02x | 4.17x | 3.97x | 3.69x |
| EV / Revenue | 4.49x | 5.04x | 5.06x | 4.29x | 4.55x | 4.72x | 4.31x | 3.78x |
| EV / EBITDA | 10.5x | 11.3x | 30.2x | 9.88x | 9.08x | 19.2x | 8.96x | 7.86x |
| EV / EBIT | 12.4x | 13.3x | 49x | 11.8x | 11.1x | 26.7x | 10.6x | 9.01x |
| EV / FCF | 25.2x | 20.3x | 33.3x | 15.2x | 24x | 26.9x | 13.3x | 11.4x |
| FCF Yield | 3.97% | 4.92% | 3.01% | 6.57% | 4.18% | 3.71% | 7.53% | 8.77% |
| Dividend per Share 2 | 2.64 | 2.8 | 2.96 | 3.12 | 3.28 | 3.344 | 3.463 | 3.674 |
| Rate of return | 3.44% | 2.52% | 2.72% | 3.14% | 3.12% | 2.96% | 3.06% | 3.25% |
| EPS 2 | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 | 2.241 | 8.312 | 9.604 |
| Distribution rate | 51.4% | 49% | 2,114% | 46.3% | 45.1% | 149% | 41.7% | 38.3% |
| Net sales 1 | 48,704 | 59,283 | 60,115 | 64,168 | 65,011 | 66,848 | 70,305 | 75,734 |
| EBITDA 1 | 20,910 | 26,431 | 10,083 | 27,897 | 32,617 | 16,449 | 33,831 | 36,383 |
| EBIT 1 | 17,696 | 22,522 | 6,211 | 23,398 | 26,779 | 11,837 | 28,667 | 31,758 |
| Net income 1 | 13,049 | 14,519 | 365 | 17,117 | 18,254 | 5,556 | 20,425 | 23,378 |
| Net Debt 1 | 25,006 | 17,499 | 27,962 | 23,869 | 34,774 | 36,379 | 23,922 | 6,933 |
| Reference price 2 | 76.64 | 110.95 | 109.02 | 99.48 | 105.26 | 113.00 | 113.00 | 113.00 |
| Nbr of stocks (in thousands) | 2,525,944 | 2,535,396 | 2,534,023 | 2,529,636 | 2,482,023 | 2,469,824 | - | - |
| Announcement Date | 2/3/22 | 2/2/23 | 2/1/24 | 2/4/25 | 2/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 50.41x | 4.72x | 19.18x | 2.96% | 279B | ||
| 29.89x | 10.84x | 22.39x | 0.67% | 909B | ||
| 24.51x | 5.65x | 15.38x | 2.33% | 552B | ||
| 25.84x | 6.38x | 13.02x | 3.23% | 375B | ||
| 17.34x | 4.33x | 10.67x | 3.06% | 332B | ||
| 23.61x | 4.9x | 13.82x | 1.78% | 291B | ||
| 20.91x | 5.6x | 13.61x | 3.02% | 287B | ||
| 13.06x | 4.8x | 9.79x | 3.86% | 199B | ||
| 21.56x | 5.83x | 10.18x | 3.04% | 179B | ||
| -47.41x | 5.64x | 31.74x | 2.48% | 162B | ||
| Average | 17.97x | 5.87x | 15.98x | 2.64% | 356.53B | |
| Weighted average by Cap. | 22.96x | 6.75x | 16.68x | 2.26% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MRK Stock
- Valuation Merck & Co., Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















